Furthermore, since MAO inhibition has been used as a recent promising multi-target approach to treat AD and PD [17,25], the ability of these RIV–BIM hybrids to inhibit both MAO isoforms (MAO-A and MAO-B) was also evaluated and complemented with docking simulations to provide some insight into the ligand–enzyme interaction. The gene discussed is MAOA; the disease is Parkinson disease.